Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentolinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 4/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentolinium SCHEMBL29479382 | 0.95 | LMNA (1.00) | LMNATSHRCYP3A4TDP1BLM | |
| Pentolinium SCHEMBL309647 | 0.95 | LMNA (1.00) | LMNATSHRCYP3A4TDP1BLM | |
| Acetic Acid SCHEMBL30330668 | 0.78 | LMNA (0.58) | LMNATSHRCYP3A4TDP1BLM | |
| Acetic Acid SCHEMBL30329921 | 0.78 | LMNA (0.58) | LMNATSHRCYP3A4TDP1BLM | |
| Acetic Acid SCHEMBL29252243 | 0.78 | LMNA (0.58) | LMNATSHRCYP3A4TDP1BLM | |
| Acetic Acid SCHEMBL29252268 | 0.78 | LMNA (0.58) | LMNATSHRCYP3A4TDP1BLM | |
| Bicarbonate SCHEMBL16760605 | 0.77 | BBOX1 (0.60) | LMNATSHRCYP3A4TDP1BLM | |
| SCHEMBL12638424 | 0.77 | BBOX1 (0.56) | LMNATSHRCYP3A4TDP1BLM | |
| SCHEMBL7593954 | 0.77 | BBOX1 (0.56) | LMNATSHRCYP3A4TDP1BLM | |
| SCHEMBL2158184 | 0.77 | BBOX1 (0.56) | LMNATSHRCYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101919822-B | Tablet with improved combination properties and preparation method thereof | ZHONG SHUGUANG | 2013-10-23 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250339496-A1 | SYSTEMS AND METHODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION | TULAVI THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3288626-B1 | SUBSTANCES AND COMPOSITIONS FOR USE IN BLOCKING NERVE REGENERATION | REFLEX MEDICAL INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250288728-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | TULAVI THERAPEUTICS INC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250127964-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | TULAVI THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| CN-1061410-A | Substituted azole, its preparation method comprises the preparation and the application thereof of substituted azole | HOECHST AG (DE) | 1992-05-27 | — | — | CN | disclosed |
| CN-1055361-A | Substituted pyrroles, process for their preparation, preparations containing them and their use | HOECHST AG (DE) | 1991-10-16 | — | — | CN | disclosed |
| US-4902720-A | Treatment of virus infections with quaternary ammonium compounds | BALTECH, INC., A CORP. OF LA | 1990-02-20 | — | — | US | disclosed |
| US-4898888-A | SUCH AS TETRAETHYLAMMONIUM OR HEXAMETHONIUM ION; HERPES SIMPLEX | BALTECH, INC. | 1990-02-06 | — | — | US | disclosed |
| US-4835157-A | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4356118-A | Tryptophan derivatives | G. D. SEARLE & CO. (US) | 1982-10-26 | — | — | US | disclosed |
| US-3980700-A | Prostaglandin intermediates and optically active isomers thereof | G. D. SEARLE & CO. (US) | 1976-09-14 | — | — | US | disclosed |
| US-3976770-A | Sar'-(OMe)Thr8 Angiotensin II as an angiotensin II antagonist | BUMPUS FRANCIS MERLIN | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | LMNA 781/4885TSHR 2997/4885CYP3A4 4820/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | LMNA 1054/4885TSHR 105/4885CYP3A4 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.